Rapid Evaporative Ionisation Mass Spectrometry for Examination of Circumferential Surgical Excision Margins
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 158
- 试验地点
- 3
- 主要终点
- Diagnostic accuracy
研究概览
简要总结
REI-EXCISE is a multicentre, prospective, non-randomised feasibility study, aimed to evaluate the diagnostic accuracy of rapid ionisation mass spectroscopy using an iKnife device. The iKnife will collect vapour, a by-product of surgery, which will pass through the mass spectrometer machine for analysis in order to evaluate what is "normal" and what is "cancerous" breast tissue.
详细描述
There is an urgent need to address high rates of close or positive margins and re-operative breast cancer surgery, which commonly results from the inability of the surgeon to rapidly and reliably evaluate resection margin status intra-operatively.
This study therefore seeks to address this problem by aiming to develop a method for near real time, in vivo intra-operative tissue classification that may be used by breast surgeons as an intelligent knife (or "iKnife") to better guide oncological margin control. The method known as Rapid Evaporative Ionisation Mass Spectrometry (REIMS) technology uses mass spectrometric and chemometric analysis of the tissue specific ionic content of the surgical diathermy smoke plume for the rapid identification of dissected breast tissues.
There are no additional treatment interventions as part of REI-EXCISE. The main study procedures are breast conserving surgery using the REIMS iKnife for mass spectral analysis of each surgical margin and correlation between the results of a software recognition algorithm that capitalised on the spectral data (i.e. iKnife margin = positive / negative) with conventional histopathological assessment. False positive iKnife data will be further interrogated with digital droplet polymerase chain reaction and imprint cytology assessment.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •BCS for ductal carcinoma in situ (B5a)
- •BCS for invasive ductal carcinoma (B5b)
- •BCS for invasive lobular carcinoma (B5b)
- •B3 lesions undergoing surgical excision
排除标准
- •Pregnant or lactating
- •18 years or younger
- •Diagnostic excision biopsy for classical lobular carcinoma in situ (LCIS) (current practice is that classical LCIS at a surgical resection margin would not mandate wider excision)
- •Or if the patient is diagnosed with
- •Non-epithelial breast tumour (phyllodes, lymphoma)
- •Note on patients receiving Neo-adjuvant Chemotherapy (NACT):
- •Patients selecting to receive NACT will be eligible for participation. However, the data for patients receiving NACT will be analysed separately as a pre-planned subgroup and these patients will not contribute data to the n=35 patients with positive margins required for this feasibility trial. Data from NACT cases have not been used to generate the validated multispectral database since eccentric fibrosis made the histological analysis more complex, which limited the number of patients in whom tissue was available for research.
结局指标
主要结局
Diagnostic accuracy
时间窗: Data collected during recruitment period: 1st June 2017 until 31st May 2019 i.e. 24 months.
The diagnostic accuracy of rapid ionisation mass spectroscopy for oncological margin status will be measured during breast conserving surgery (BCS) (n=35 patients with positive margins). The primary end-point will allow to report accuracy (sensitivity and specify) of rapid ionisation mass spectroscopy to distinguish between patients with at least one close or positive margin and those without close or positive margin.
次要结局
- Accuracy of predicting oncological status(Data collected during recruitment period: 1st June 2017 until 31st May 2019 i.e. 24 months.)
- Assessment of procedure duration using REIMS(Data collected during recruitment period: 1st June 2017 until 31st May 2019 i.e. 24 months.)
- REIMS technology user satisfaction(Data collected during recruitment period: 1st June 2017 until 31st May 2019 i.e. 24 months.)